Antengene
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A commercial-stage biotech developing and commercializing novel oncology and immunology drugs, with a flagship product already launched in China.
OncologyImmunology
Technology Platform
Platform focused on protein homeostasis and degradation, including molecular glue degraders, to target oncogenic drivers.
Opportunities
Significant opportunity to expand the label and geographic reach of its lead asset while advancing its novel preclinical pipeline.
Risk Factors
Heavy reliance on a single commercial product and intense pricing pressure in the Chinese oncology market pose key risks.
Competitive Landscape
Operates in the highly competitive oncology space, competing with large global pharma and numerous Chinese biotechs, but differentiated by its commercial footprint and protein degradation focus.